- Home
- IMCR vs PTGX Comparison
IMCR vs PTGX Comparison
Compare IMCR & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- PTGX
- Stock Information
- Founded
- IMCR 2008
- PTGX 2006
- Country
- IMCR United Kingdom
- PTGX United States
- Employees
- IMCR N/A
- PTGX N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- IMCR Health Care
- PTGX Health Care
- Exchange
- IMCR Nasdaq
- PTGX Nasdaq
- Market Cap
- IMCR 1.7B
- PTGX 2.8B
- IPO Year
- IMCR 2021
- PTGX 2016
- Fundamental
- Price
- IMCR $32.93
- PTGX $47.91
- Analyst Decision
- IMCR Buy
- PTGX Strong Buy
- Analyst Count
- IMCR 14
- PTGX 7
- Target Price
- IMCR $74.75
- PTGX $52.83
- AVG Volume (30 Days)
- IMCR 267.8K
- PTGX 450.1K
- Earning Date
- IMCR 11-05-2024
- PTGX 11-08-2024
- Dividend Yield
- IMCR N/A
- PTGX N/A
- EPS Growth
- IMCR N/A
- PTGX N/A
- EPS
- IMCR N/A
- PTGX 2.75
- Revenue
- IMCR $280,914,000.00
- PTGX $319,120,000.00
- Revenue This Year
- IMCR $25.60
- PTGX $400.33
- Revenue Next Year
- IMCR $10.63
- PTGX N/A
- P/E Ratio
- IMCR N/A
- PTGX $17.54
- Revenue Growth
- IMCR 27.95
- PTGX 125.73
- 52 Week Low
- IMCR $29.72
- PTGX $13.76
- 52 Week High
- IMCR $76.98
- PTGX $48.89
- Technical
- Relative Strength Index (RSI)
- IMCR 52.76
- PTGX 60.40
- Support Level
- IMCR $31.10
- PTGX $45.33
- Resistance Level
- IMCR $35.47
- PTGX $48.89
- Average True Range (ATR)
- IMCR 1.49
- PTGX 1.28
- MACD
- IMCR 0.17
- PTGX 0.11
- Stochastic Oscillator
- IMCR 51.98
- PTGX 77.11
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.